Results 31 to 40 of about 8,944 (181)

Adverse Effects Associated with Diazoxide Use in Neonates [PDF]

open access: yes, 2022
Introduction: Diazoxide is the first-line treatment used to manage infants and children with hypoglycemia secondary to hyperinsulinemic hypoglycemia (HH), after initial stabilization of blood glucose.
Graber, Evan   +3 more
core   +1 more source

The mitochondrial K-ATP channel opener diazoxide upregulates STIM1 and Orai1 via ROS and the MAPK pathway in adult rat cardiomyocytes

open access: yesCell & Bioscience, 2020
Background Openers of mitochondrial adenosine triphosphate-dependent potassium (mKATP) channels like diazoxide increase reactive oxygen species (ROS) production in cardiac cells and reduce Ca2+ elevations produced by ischemia–reperfusion, protecting the ...
Joice T. Gavali   +3 more
doaj   +1 more source

Effect Of Diazoxide on Friedreich Ataxia Models [PDF]

open access: yes, 2018
Friedreich ataxia (FRDA) is an inherited recessive disorder caused by a deficiency in the mitochondrial protein frataxin. There is currently no effective treatment for FRDA available, especially for neurological deficits.
Vito Porcelli   +44 more
core   +2 more sources

Diazoxide protects myocardial mitochondria, metabolism, and function during cardiac surgery: A double-blind randomized feasibility study of diazoxide-supplemented cardioplegia [PDF]

open access: yes, 2009
ObjectivesThe study was designed to assess whether diazoxide-mediated cardioprotection might be used in human subjects during cardiac surgery.MethodsForty patients undergoing coronary artery bypass grafting were randomized to receive intermittent warm ...
Kajor, Maciej   +10 more
core   +1 more source

Diazoxide and Exercise Enhance Muscle Contraction during Obesity by Decreasing ROS Levels, Lipid Peroxidation, and Improving Glutathione Redox Status

open access: yesAntioxidants, 2020
Obesity causes insulin resistance and hyperinsulinemia which causes skeletal muscle dysfunction resulting in a decrease in contraction force and a reduced capacity to avoid fatigue, which overall, causes an increase in oxidative stress.
Mariana Gómez-Barroso   +6 more
doaj   +1 more source

The danger of diazoxide in the neonatal intensive care unit

open access: yesTherapeutic Advances in Drug Safety, 2021
Background: The most common cause of persistent hypoglycemia in infancy is hyperinsulinemic hypoglycemia. When conservative measures fail, providers often use medications to treat persistent hypoglycemia.
Jay Desai   +4 more
doaj   +1 more source

Combined Effects of Diazoxide and Moderate-Intensity Exercise on the Restoration of Redox Balance Post-Fatigue in Fast- and Slow-Twitch Skeletal Muscles of Hypertensive Rats

open access: yesBiology
Muscle fatigue, defined as a decline in force generation, is closely linked to redox imbalance—a condition exacerbated by oxidative stress in hypertension. This study investigated the effects of diazoxide administration and moderate-intensity exercise on
Estefanía Bravo-Sánchez   +10 more
doaj   +1 more source

Partial diazoxide responsiveness in a neonate with hyperinsulinism due to homozygous ABCC8 mutation

open access: yesEndocrinology, Diabetes & Metabolism Case Reports, 2019
We report a case of partial diazoxide responsiveness in a child with severe congenital hyperinsulinaemic hypoglycaemia (CHI) due to a homozygous ABCC8 mutation.
Sarah Kiff   +9 more
doaj   +1 more source

A New Case of Lethal Congenital Contracture Syndrome Type 3 With Hyperinsulinism and Optic Atrophy

open access: yesClinical Genetics, EarlyView.
PIP5K1C‐related lethal congenital contracture syndrome with hyperinsulinism and optic atrophy. ABSTRACT Lethal congenital contracture syndrome 3 (LCCS3, MIM #611369) is a rare autosomal recessive neuromuscular disorder caused by biallelic loss‐of‐function (LOF) variants in PIP5K1C, reported in only two families to date.
Tameemi Abdalla Moady   +3 more
wiley   +1 more source

Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis.

open access: yesPLoS ONE, 2021
Diazoxide is the first-line drug for treating hyperinsulinism and the only pharmacological agent approved for hyperinsulinism by the Federal Drug Administration.
Xiaohong Chen   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy